The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma

Cenk Gurbuz, Ramy F. Youssef, Shahrokh F. Shariat, Yair Lotan, Christopher G. Wood, Arthur I Sagalowsky, Richard Zigeuner, Eiji Kikuchi, Alon Weizer, Jay D. Raman, Mesut Remzi, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Vitaly Margulis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We investigated whether a history of endoscopic tumor ablation impacts oncologic outcomes after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Using a multi-institutional database that contained patients who were treated with RNU, oncologic outcomes were assessed according to history of ureteroscopic tumor ablation. Disease-free survival (DFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier survival analysis. Multivariate Cox regression analyses were performed to determine independent predictors of disease recurrence and cancer-specific mortality after RNU. The study included 1268 patients, 853 men and 415 women, with a mean age of 67.5 years (range 32-94 y) and 52.8 months median follow-up after RNU. A total of 175 (13%) patients underwent RNU after endoscopic tumor ablation and 1093 (87%) patients underwent RNU without a history of endoscopic ablation. The 5-year DFS and CSS rates were 72% and 77% in those with a history of tumor ablation vs 69% and 73% in those without a history of ablation (P = 0.171 and P = 0.365, respectively). In multivariate Cox regression analysis, history of ablation therapy was not associated with disease recurrence or cancer-specific mortality (hazard ratio [HR]: 0.79, P = 0.185 and HR: 0.7, P = 0.078, respectively). Our collaborative international efforts suggest that in selected patients, endoscopic tumor ablation does not adversely affect the recurrence and survival after subsequent RNU for UTUC. Our data support the continued role of ureteroscopic ablation of UTUC in appropriately selected patients.

Original languageEnglish (US)
Pages (from-to)775-779
Number of pages5
JournalJournal of Endourology
Volume25
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Urinary Tract
Carcinoma
Neoplasms
Recurrence
Disease-Free Survival
Regression Analysis
Survival
Mortality
Kaplan-Meier Estimate
Survival Analysis
Survival Rate
Databases

ASJC Scopus subject areas

  • Urology

Cite this

The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. / Gurbuz, Cenk; Youssef, Ramy F.; Shariat, Shahrokh F.; Lotan, Yair; Wood, Christopher G.; Sagalowsky, Arthur I; Zigeuner, Richard; Kikuchi, Eiji; Weizer, Alon; Raman, Jay D.; Remzi, Mesut; Roscigno, Marco; Montorsi, Francesco; Bolenz, Christian; Kassouf, Wassim; Margulis, Vitaly.

In: Journal of Endourology, Vol. 25, No. 5, 01.05.2011, p. 775-779.

Research output: Contribution to journalArticle

Gurbuz, C, Youssef, RF, Shariat, SF, Lotan, Y, Wood, CG, Sagalowsky, AI, Zigeuner, R, Kikuchi, E, Weizer, A, Raman, JD, Remzi, M, Roscigno, M, Montorsi, F, Bolenz, C, Kassouf, W & Margulis, V 2011, 'The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma', Journal of Endourology, vol. 25, no. 5, pp. 775-779. https://doi.org/10.1089/end.2010.0396
Gurbuz, Cenk ; Youssef, Ramy F. ; Shariat, Shahrokh F. ; Lotan, Yair ; Wood, Christopher G. ; Sagalowsky, Arthur I ; Zigeuner, Richard ; Kikuchi, Eiji ; Weizer, Alon ; Raman, Jay D. ; Remzi, Mesut ; Roscigno, Marco ; Montorsi, Francesco ; Bolenz, Christian ; Kassouf, Wassim ; Margulis, Vitaly. / The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. In: Journal of Endourology. 2011 ; Vol. 25, No. 5. pp. 775-779.
@article{d0df680bf6d24e948db3b8a584045e67,
title = "The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma",
abstract = "We investigated whether a history of endoscopic tumor ablation impacts oncologic outcomes after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Using a multi-institutional database that contained patients who were treated with RNU, oncologic outcomes were assessed according to history of ureteroscopic tumor ablation. Disease-free survival (DFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier survival analysis. Multivariate Cox regression analyses were performed to determine independent predictors of disease recurrence and cancer-specific mortality after RNU. The study included 1268 patients, 853 men and 415 women, with a mean age of 67.5 years (range 32-94 y) and 52.8 months median follow-up after RNU. A total of 175 (13{\%}) patients underwent RNU after endoscopic tumor ablation and 1093 (87{\%}) patients underwent RNU without a history of endoscopic ablation. The 5-year DFS and CSS rates were 72{\%} and 77{\%} in those with a history of tumor ablation vs 69{\%} and 73{\%} in those without a history of ablation (P = 0.171 and P = 0.365, respectively). In multivariate Cox regression analysis, history of ablation therapy was not associated with disease recurrence or cancer-specific mortality (hazard ratio [HR]: 0.79, P = 0.185 and HR: 0.7, P = 0.078, respectively). Our collaborative international efforts suggest that in selected patients, endoscopic tumor ablation does not adversely affect the recurrence and survival after subsequent RNU for UTUC. Our data support the continued role of ureteroscopic ablation of UTUC in appropriately selected patients.",
author = "Cenk Gurbuz and Youssef, {Ramy F.} and Shariat, {Shahrokh F.} and Yair Lotan and Wood, {Christopher G.} and Sagalowsky, {Arthur I} and Richard Zigeuner and Eiji Kikuchi and Alon Weizer and Raman, {Jay D.} and Mesut Remzi and Marco Roscigno and Francesco Montorsi and Christian Bolenz and Wassim Kassouf and Vitaly Margulis",
year = "2011",
month = "5",
day = "1",
doi = "10.1089/end.2010.0396",
language = "English (US)",
volume = "25",
pages = "775--779",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma

AU - Gurbuz, Cenk

AU - Youssef, Ramy F.

AU - Shariat, Shahrokh F.

AU - Lotan, Yair

AU - Wood, Christopher G.

AU - Sagalowsky, Arthur I

AU - Zigeuner, Richard

AU - Kikuchi, Eiji

AU - Weizer, Alon

AU - Raman, Jay D.

AU - Remzi, Mesut

AU - Roscigno, Marco

AU - Montorsi, Francesco

AU - Bolenz, Christian

AU - Kassouf, Wassim

AU - Margulis, Vitaly

PY - 2011/5/1

Y1 - 2011/5/1

N2 - We investigated whether a history of endoscopic tumor ablation impacts oncologic outcomes after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Using a multi-institutional database that contained patients who were treated with RNU, oncologic outcomes were assessed according to history of ureteroscopic tumor ablation. Disease-free survival (DFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier survival analysis. Multivariate Cox regression analyses were performed to determine independent predictors of disease recurrence and cancer-specific mortality after RNU. The study included 1268 patients, 853 men and 415 women, with a mean age of 67.5 years (range 32-94 y) and 52.8 months median follow-up after RNU. A total of 175 (13%) patients underwent RNU after endoscopic tumor ablation and 1093 (87%) patients underwent RNU without a history of endoscopic ablation. The 5-year DFS and CSS rates were 72% and 77% in those with a history of tumor ablation vs 69% and 73% in those without a history of ablation (P = 0.171 and P = 0.365, respectively). In multivariate Cox regression analysis, history of ablation therapy was not associated with disease recurrence or cancer-specific mortality (hazard ratio [HR]: 0.79, P = 0.185 and HR: 0.7, P = 0.078, respectively). Our collaborative international efforts suggest that in selected patients, endoscopic tumor ablation does not adversely affect the recurrence and survival after subsequent RNU for UTUC. Our data support the continued role of ureteroscopic ablation of UTUC in appropriately selected patients.

AB - We investigated whether a history of endoscopic tumor ablation impacts oncologic outcomes after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Using a multi-institutional database that contained patients who were treated with RNU, oncologic outcomes were assessed according to history of ureteroscopic tumor ablation. Disease-free survival (DFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier survival analysis. Multivariate Cox regression analyses were performed to determine independent predictors of disease recurrence and cancer-specific mortality after RNU. The study included 1268 patients, 853 men and 415 women, with a mean age of 67.5 years (range 32-94 y) and 52.8 months median follow-up after RNU. A total of 175 (13%) patients underwent RNU after endoscopic tumor ablation and 1093 (87%) patients underwent RNU without a history of endoscopic ablation. The 5-year DFS and CSS rates were 72% and 77% in those with a history of tumor ablation vs 69% and 73% in those without a history of ablation (P = 0.171 and P = 0.365, respectively). In multivariate Cox regression analysis, history of ablation therapy was not associated with disease recurrence or cancer-specific mortality (hazard ratio [HR]: 0.79, P = 0.185 and HR: 0.7, P = 0.078, respectively). Our collaborative international efforts suggest that in selected patients, endoscopic tumor ablation does not adversely affect the recurrence and survival after subsequent RNU for UTUC. Our data support the continued role of ureteroscopic ablation of UTUC in appropriately selected patients.

UR - http://www.scopus.com/inward/record.url?scp=79957595346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957595346&partnerID=8YFLogxK

U2 - 10.1089/end.2010.0396

DO - 10.1089/end.2010.0396

M3 - Article

C2 - 21388245

AN - SCOPUS:79957595346

VL - 25

SP - 775

EP - 779

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 5

ER -